Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Post author: Post published:March 17, 2026 Post category: Continue ReadingOrca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia Post author: Post published:March 17, 2026 Post category: Continue ReadingCD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
T-Cell Therapy (ECT204) in Adults With Advanced HCC Post author: Post published:March 17, 2026 Post category: Continue ReadingT-Cell Therapy (ECT204) in Adults With Advanced HCC
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingCS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingGenetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol Post author: Post published:March 17, 2026 Post category: Continue ReadingNonconforming Lisocabtagene Maraleucel Expanded Access Protocol
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingStudy of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin’s Lymphoma
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma Post author: Post published:March 17, 2026 Post category: Continue ReadingA Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
